Pulse Biosciences (PLSE) news

Pulse Biosciences announces commercial and clinical partnership with the Clayman Thyroid Center

Pulse Biosciences Inc.: Oppenheimer raises target price to $60 from $35

Oppenheimer & Co. has raised its price target for Pulse Biosciences Inc. (PULS) to $60 from $35, reflecting a more optimistic outlook on the company’s growth potential and market positioning. The adjustment comes amid ongoing developments in the biotechnology sector and increased investor interest…

Pulse Biosciences Inc: Canaccord Genuity raises target price to $58 from $43

Canaccord Genuity has revised its price target for Pulse Biosciences Inc (NASDAQ:PLSE), raising it to $58 from $43, reflecting a positive outlook on the company’s potential performance. The updated target suggests increased confidence in the firm’s strategic direction and market positioning. Pulse…

Pulse Biosciences - Terminates TD Cowen distribution agreement on Sept 14, 2026 with $1 mln unsold - SEC filing

Pulse Biosciences, Inc. (NASDAQ: PLSE) has filed with the U.S. Securities and Exchange Commission (SEC) to terminate its at-the-market (ATM) equity distribution agreement with TD Cowen, effective September 14, 2026. At the time of termination, approximately $1 million remained unsold of the $59.98…

Pulse Biosciences - Enters equity distribution agreement with Mizuho for up to $85 mln - SEC filing

Pulse Biosciences, Inc. (PLSE) has entered into an equity distribution agreement with Mizuho Securities USA LLC to sell up to $75 million of its common stock through at-the-market offerings under an existing shelf registration, according to a recent SEC filing. Under the terms of the agreement,…